Who are BT5528's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): mini CYVE, without 3 maintenance courses, MB-102 DMID, MB-102 OMID, [68Ga]Ga-PentixaFor, Open single period A140, Treatment Choice (TC).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bt5528.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BT5528 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BT5528 (BT5528) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD47/SIRPα inhibitor. Area: Oncology.

phase 2 CD47/SIRPα inhibitor CD47 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BT5528 (BT5528) — BicycleTx Limited. BT5528 is a small molecule inhibitor of the CD47/SIRPα axis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BT5528 TARGET	BT5528	BicycleTx Limited	phase 2	CD47/SIRPα inhibitor	CD47
mini CYVE, without 3 maintenance courses	mini CYVE, without 3 maintenance courses	Gustave Roussy, Cancer Campus, Grand Paris	phase 3	CD47/SIRPα inhibitor	CD47
MB-102 DMID	MB-102 DMID	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	phase 3	monoclonal antibody	CD47
MB-102 OMID	MB-102 OMID	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	phase 3	CD47 inhibitor	CD47
[68Ga]Ga-PentixaFor	[68Ga]Ga-PentixaFor	Nantes University Hospital	phase 3	Radiopharmaceutical	CD47
Open single period A140	Open single period A140	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	phase 3	CD47 inhibitor	CD47
Treatment Choice (TC)	Treatment Choice (TC)	Astex Pharmaceuticals, Inc.	phase 3	SIRPα inhibitor	CD47

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD47/SIRPα inhibitor class)

BicycleTx Limited · 1 drug in this class
Gustave Roussy, Cancer Campus, Grand Paris · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Kuhnil Pharmaceutical Co., Ltd. · 1 drug in this class
Merck KGaA, Darmstadt, Germany · 1 drug in this class
Pharmicell Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BT5528 — Competitive Intelligence Brief. https://druglandscape.com/ci/bt5528. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing